Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996467 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL15932531 | 0.90 | SLC1A3 (0.53) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL22648528 | 0.89 | SLC1A3 (0.56) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL3992135 | 0.88 | SLC1A3 (0.52) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL5984332 | 0.88 | SLC1A3 (0.52) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL18086889 | 0.87 | CTSK (0.55) | CTSKHSD17B10CTSSSYKCTSL | |
| SCHEMBL4602331 | 0.86 | HSD17B10 (0.60) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL16371929 | 0.86 | HSD17B10 (0.60) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL26030817 | 0.86 | HSD17B10 (0.60) | SLC1A3SLC1A1CTSKHSD17B10CTSS | |
| SCHEMBL1734009 | 0.84 | CTSL (0.56) | SLC1A3SLC1A1CTSKHSD17B10CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090036487-A1 | Combinations | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-7419981-B2 | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor | PFIZER INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1536782-B1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| EP-1670452-A2 | METHOD OF USE OF AMINOACIDS HAVING AFFINITY FOR THE A2D PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1667722-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | Pfizer Limited (GB) | 2006-06-14 | — | — | EP | disclosed |
| EP-1536782-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | disclosed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036487-A1 | Combinations | CHRNE, CHRND, CHRNG | SLC1A3 903/4885SLC1A1 1090/4885CTSK 1018/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | SLC1A3 1462/4885SLC1A1 1311/4885CTSK 1929/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | SLC1A3 73/4885SLC1A1 67/4885CTSK 3115/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | SLC1A3 103/4885SLC1A1 97/4885CTSK 2923/4885 |
| US-20050065176-A1 | Combinations | CHRNE, CHRND, CHRNG | SLC1A3 903/4885SLC1A1 1090/4885CTSK 1018/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | SLC1A3 1462/4885SLC1A1 1311/4885CTSK 1929/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | SLC1A3 102/4885SLC1A1 94/4885CTSK 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.